Tenapanor 50 MG

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Development History

Sep '26

ARDXPhase 3$1.5B

Tenapanor 50 MG Phase 3 Est. Readout

Tenapanor 50 MG• Irritable Bowel Syndrome With Constipation (IBS-C)180

Sep 2026~Confirmed

00%

Competitive Landscape

0 competitors in Irritable Bowel Syndrome With Constipation (IBS-C)

Drug Information

Target Indication

Irritable Bowel Syndrome With Constipation (IBS-C)

Clinical Trial

Last updated: 12/23/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

ARDX

Ardelyx

Related Pipeline

Chronic Idiopathic Constipation (CIC)

Hyperphosphatemia

Hyperphosphatemia

Hyperphosphatemia

Chronic Kidney Disease

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts